Lexeo Therapeutics, Inc. Common Stock (LXEO) — Strategic Asset Allocation Index
Lexeo Therapeutics, Inc. Common Stock (LXEO) has a Strategic Asset Allocation Index of 16.4% as of March 2026. Strategic assets (PP&E of $- plus long-term investments of $37.90 Million) total $37.90 Million, measured against net assets of $231.50 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check Lexeo Therapeutics, Inc. Common Stock (LXEO) asset resilience to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Lexeo Therapeutics, Inc. Common Stock Strategic Asset Allocation Index (2023–2025)
This chart shows how Lexeo Therapeutics, Inc. Common Stock's Strategic Asset Allocation Index has evolved across 3 annual periods from 2023 to 2025. As of March 2026, the index stands at 16.4%, representing strategic assets of $37.90 Million against net assets of $231.50 Million USD. See financial flexibility index of Lexeo Therapeutics, Inc. Common Stock to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Lexeo Therapeutics, Inc. Common Stock (2023–2025)
The table below presents the year-by-year Strategic Asset Allocation Index for Lexeo Therapeutics, Inc. Common Stock from 2023 to 2025, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Lexeo Therapeutics, Inc. Common Stock (LXEO) total market value.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 27.6% | $68.19 Million | $- | $68.19 Million | $246.67 Million | ▲ +21.6 pp |
| 2024 | 6.0% | $7.01 Million | $- | $7.01 Million | $116.84 Million | ▲ +6.0 pp |
| 2023 | 0.0% | $0.00 | $- | $0.00 | $113.53 Million | — |